A recent study reveals that people who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds far faster than those who end conventional lifestyle plans.
Published data in a major health publication demonstrates that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Individuals using such drugs must be aware of the potential of fast rebound weight gain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to original weight within about a year and a half.
Comparing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers note that people who lose weight through diet and exercise generally have a more gradual weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Doctors believe the mode of action of the jabs accounts for the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating far more likely."
A Lifelong Issue?
The NHS advise the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, given the high risk of weight regain, the treatment should be considered life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Individuals who have discontinued the jabs report a intense return of hunger.
"It was like a trigger flipping and I was suddenly starving," described an individual.
The struggle is compounded if patients have not adopted lasting lifestyle or habit changes during therapy.
Significant Adoption
Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on integrated behavioural changes.
